[go: up one dir, main page]

Pelizaeus-Merzbacher Disease

"Pelizaeus-Merzbacher Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

expand / collapse MeSH information
A rare, slowly progressive disorder of myelin formation. Subtypes are referred to as classic, congenital, transitional, and adult forms of this disease. The classic form is X-chromosome linked, has its onset in infancy and is associated with a mutation of the proteolipid protein gene. Clinical manifestations include TREMOR, spasmus nutans, roving eye movements, ATAXIA, spasticity, and NYSTAGMUS, CONGENITAL. Death occurs by the third decade of life. The congenital form has similar characteristics but presents early in infancy and features rapid disease progression. Transitional and adult subtypes have a later onset and less severe symptomatology. Pathologic features include patchy areas of demyelination with preservation of perivascular islands (trigoid appearance). (From Menkes, Textbook of Child Neurology, 5th ed, p190)


expand / collapse Publications
This graph shows the total number of publications written about "Pelizaeus-Merzbacher Disease" by people in this website by year, and whether "Pelizaeus-Merzbacher Disease" was a major or minor topic of these publications.
Below are the most recent publications written about "Pelizaeus-Merzbacher Disease" by people in Profiles.
  1. Generation of functional human oligodendrocytes from dermal fibroblasts by direct lineage conversion. Development. 2022 10 15; 149(20).
    View in: PubMed
  2. Suppression of proteolipid protein rescues Pelizaeus-Merzbacher disease. Nature. 2020 09; 585(7825):397-403.
    View in: PubMed
  3. Estimating the relative frequency of leukodystrophies and recommendations for carrier screening in the era of next-generation sequencing. Am J Med Genet A. 2020 08; 182(8):1906-1912.
    View in: PubMed
  4. Oligodendrocyte Death in Pelizaeus-Merzbacher Disease Is Rescued by Iron Chelation. Cell Stem Cell. 2019 Oct 03; 25(4):531-541.e6.
    View in: PubMed
  5. Long-Term Safety, Immunologic Response, and Imaging Outcomes following Neural Stem Cell Transplantation for Pelizaeus-Merzbacher Disease. Stem Cell Reports. 2019 08 13; 13(2):254-261.
    View in: PubMed
  6. Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports. 2018 09 11; 11(3):711-726.
    View in: PubMed
  7. Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes. Am J Hum Genet. 2017 Apr 06; 100(4):617-634.
    View in: PubMed
  8. Concise Review: Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease. Stem Cells. 2017 02; 35(2):311-315.
    View in: PubMed
  9. Pelizaeus Merzbacher disease: dysmyelination versus demyelination. Arq Neuropsiquiatr. 2016 Jan; 74(1):81.
    View in: PubMed
  10. A large genomic deletion leads to enhancer adoption by the lamin B1 gene: a second path to autosomal dominant adult-onset demyelinating leukodystrophy (ADLD). Hum Mol Genet. 2015 Jun 01; 24(11):3143-54.
    View in: PubMed